v3.26.1
Other Expense (Income)
 6 Months Ended
Jun. 30, 2026
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consists of:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Restructuring and related charges$2.3 $0.2 $4.1 $16.6 
Contingent consideration3.2 2.2 6.2 4.6 
Asset impairments3.9 0.8 4.2 1.1 
Foreign exchange transaction losses1.9 1.7 3.0 2.9 
(Gain) loss on oil hedges1.0 0.2 (0.9)0.4 
Other items0.5 0.1 0.2 0.2 
Total other expense (income)$12.8 $5.2 $16.8 $25.8 
Restructuring and Related Charges
In January 2025, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of approximately twenty-four to thirty-six months from the date of approval. The plan is expected to require restructuring and related charges of approximately $28 million to $30 million, with annualized savings in the range of $35 million to $40 million. The following table presents activity related to our restructuring obligations related to our January 2025 restructuring plan:
($ in millions)Severance
and benefits		Asset-related chargesTotal
Balance, December 31, 2025$6.9 $— $6.9 
Charges (Credits)— 1.9 1.9 
Cash payments(0.2)— (0.2)
Non-cash asset write downs— (1.9)(1.9)
Balance, June 30, 2026$6.7 $— $6.7 
In December 2025, the Company approved a restructuring plan related to a definitive agreement to sell all manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. These changes are expected to be implemented over a period of approximately twelve to fifteen months from the date of approval. The plan is expected to require restructuring and related charges of $12 million to $16 million, with annualized savings in the range of $15 million to $20 million. The following table presents activity related to our restructuring obligations related to our December 2025 restructuring plan:
($ in millions)Severance
and benefits		Total
Balance, December 31, 2025$4.2 $4.2 
Charges (Credits)2.2 2.2 
Balance, June 30, 2026$6.4 $6.4 
Contingent Consideration
Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.
Asset Impairments
The Company's asset impairment expense includes impairment charges to its cost-method investments and expense related to fixed assets impaired or taken out of service. During the periods ended June 30, asset impairments consisted of:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2026202520262025
Cost-method investment impairment charges$3.5 $— $3.5 $— 
Fixed asset impairment expense0.4 0.8 0.7 1.1 
Total asset impairments$3.9 $0.8 $4.2 $1.1